Skip to main content
Top
Published in: Pediatric Drugs 6/2016

01-12-2016 | Original Research Article

Tablet Splitting of Antiepileptic Drugs in Pediatric Epilepsy: Potential Effect on Plasma Drug Concentrations

Authors: Ravi Prasad Nidanapu, Sundaram Rajan, Subramanian Mahadevan, Batmanabane Gitanjali

Published in: Pediatric Drugs | Issue 6/2016

Login to get access

Abstract

Introduction

Tablet splitting is the process of dividing a tablet into portions to obtain a prescribed dose of medication. Very few studies have investigated whether split parts of a tablet deliver the expected amount of drug to patients.

Objective

Our objectives were to evaluate the split parts of adult-dose tablet formulations for percentage of weight deviation, weight uniformity, weight loss, drug content, and the content uniformity of four antiepileptic drugs (AEDs) prescribed to pediatric patients. We also measured AED plasma concentrations in the children.

Methods

We chose to study first-line AEDs (phenytoin sodium [PHE], sodium valproate [SVA], carbamazepine, and phenobarbitone) as they are routinely prescribed in India. We asked caregivers to perform the same splitting process they follow in their homes on three whole tablets during their routine visit to the outpatient department. After caregivers split the tablets, we studied the weight and content of the split parts. We also used high-performance liquid chromatography to study plasma drug concentrations in children who had received split AEDs for at least 4 months.

Results

A total of 168 caregivers participated in the study, and we analyzed 1098 split tablet parts. In total, 539 (49.0 %) split parts were above the specified limit of the 2010 Indian Pharmacopeia (IP) acceptable percentage weight deviation (PHE 169 [48.8 %], SVA 187 [51.9 %], carbamazepine 56 [41.1 %], phenobarbitone 127 [49.6 %]); 456 (41.5 %) split parts were outside the proxy IP specification for drug content (PHE 135 [39.0 %], SVA 140 [38.8 %], carbamazepine 51 [37.5 %], phenobarbitone 130 [50.7 %]), and 253 split parts were outside the acceptable content uniformity range of <85 % and >115 % (PHE 85 [24.5 %], SVA 98 [27.2 %], carbamazepine 14 [10.2 %], phenobarbitone 56 [21.8 %]). In total, 130 (72.2 %) patients had plasma drug concentrations outside the therapeutic range (PHE 36 [72.0 %], SVA 39 [78.0 %], carbamazepine 34 [68.0 %], phenobarbitone 21 [70.0 %]).

Conclusions

Splitting adult-dosage formulations of AEDs results in patients not receiving the optimal dose. Plasma drug concentrations are also not optimal. Pediatric dosage formulations should be preferred to splitting adult-dosage formulations in pediatric epilepsy.
Literature
1.
go back to reference Zaid AN, Al-Ramahi R, Ghoush AA, Malkieh N, Kharoaf M. Influence of physical factors on tablet splitting, weight and content uniformity of atenolol tablets. J Pharm Investig. 2012;42:229–34.CrossRef Zaid AN, Al-Ramahi R, Ghoush AA, Malkieh N, Kharoaf M. Influence of physical factors on tablet splitting, weight and content uniformity of atenolol tablets. J Pharm Investig. 2012;42:229–34.CrossRef
2.
go back to reference Duncan MC, Castle SS, Streetman DS. Effect of tablet splitting on serum cholesterol concentrations. Ann Pharmacother. 2002;36:205–9.CrossRefPubMed Duncan MC, Castle SS, Streetman DS. Effect of tablet splitting on serum cholesterol concentrations. Ann Pharmacother. 2002;36:205–9.CrossRefPubMed
3.
go back to reference Fawell NG, Cookson TL, Scranton SS. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance. Am J Health Syst Pharm. 1999;56:2542–5.PubMed Fawell NG, Cookson TL, Scranton SS. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance. Am J Health Syst Pharm. 1999;56:2542–5.PubMed
4.
go back to reference Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol. 2006;62:1065–73.CrossRefPubMed Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol. 2006;62:1065–73.CrossRefPubMed
5.
go back to reference De Spiegeleer B, Van Hoorebeke L, De Spiegeleer A, Castelein P, Van Bortel L. The paradox of scored tablets: a cost-saving risk. Pharmazie. 2009;64:550–2.PubMed De Spiegeleer B, Van Hoorebeke L, De Spiegeleer A, Castelein P, Van Bortel L. The paradox of scored tablets: a cost-saving risk. Pharmazie. 2009;64:550–2.PubMed
6.
go back to reference Wilson MMG, Kaiser FE, Morley JE. Tablet-breaking ability of older persons with type 2 diabetes mellitus. Diabetes Educ. 2001;27:530–40.CrossRefPubMed Wilson MMG, Kaiser FE, Morley JE. Tablet-breaking ability of older persons with type 2 diabetes mellitus. Diabetes Educ. 2001;27:530–40.CrossRefPubMed
8.
go back to reference Nunn A, Richey R, Shah U, Barker C, Craig J, Peak M, et al. Estimating the requirement for manipulation of medicines to provide accurate doses for children. Eur J Hosp Pharm. 2013;20:3–7.CrossRef Nunn A, Richey R, Shah U, Barker C, Craig J, Peak M, et al. Estimating the requirement for manipulation of medicines to provide accurate doses for children. Eur J Hosp Pharm. 2013;20:3–7.CrossRef
9.
go back to reference McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy. 1998;18:193–7.PubMed McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy. 1998;18:193–7.PubMed
10.
go back to reference Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS Pharm Sci Tech. 2010;11:1359–67.CrossRef Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS Pharm Sci Tech. 2010;11:1359–67.CrossRef
11.
go back to reference Chou CL, Hsu CC, Chou CY, Chen TJ, Chou LF, Chou YC. Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan. Int J Clin Pharm. 2015;37:1235–41.CrossRefPubMed Chou CL, Hsu CC, Chou CY, Chen TJ, Chou LF, Chou YC. Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan. Int J Clin Pharm. 2015;37:1235–41.CrossRefPubMed
12.
13.
go back to reference Mosena MS, Van der Merwe E. The appropriateness and risks of tablet splitting. SA Pharm J. 2009;76:30–6. Mosena MS, Van der Merwe E. The appropriateness and risks of tablet splitting. SA Pharm J. 2009;76:30–6.
14.
go back to reference Swain TR, Rath B, Dehury S, Tarai A, Das P, Samal R, et al. Pricing and availability of some essential child specific medicines in Odisha. Indian J Pharmacol. 2015;47:496–501.CrossRefPubMedPubMedCentral Swain TR, Rath B, Dehury S, Tarai A, Das P, Samal R, et al. Pricing and availability of some essential child specific medicines in Odisha. Indian J Pharmacol. 2015;47:496–501.CrossRefPubMedPubMedCentral
15.
go back to reference Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–76.CrossRefPubMed Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–76.CrossRefPubMed
16.
go back to reference India, Indian Pharmacopoeia Commission, (editors). Indian pharmacopoeia, 2010. Sixth edition. Ghaziabad: Indian Pharmacopoeia Commission; 2010. India, Indian Pharmacopoeia Commission, (editors). Indian pharmacopoeia, 2010. Sixth edition. Ghaziabad: Indian Pharmacopoeia Commission; 2010.
17.
go back to reference Zaid AN, Ghoush AA, Al-Ramahi R, Are’r M. Evaluation of the discrepancy between the european pharmacopoeia test and an adopted United States pharmacopoeia test regarding the weight uniformity of scored tablet halves: is harmonization required? J Pharm Sci Technol. 2012;66:20–7. Zaid AN, Ghoush AA, Al-Ramahi R, Are’r M. Evaluation of the discrepancy between the european pharmacopoeia test and an adopted United States pharmacopoeia test regarding the weight uniformity of scored tablet halves: is harmonization required? J Pharm Sci Technol. 2012;66:20–7.
18.
go back to reference De Spiegeleer B, Vooren LV, Thonissen T, Joye P, Cornelissen B, Lammens G, et al. Mass uniformity: influence of operational compression conditions on breakability of scored tablets as part of manufacturing robustness evaluation. J Food Drug Anal. 2005;13:22–9. De Spiegeleer B, Vooren LV, Thonissen T, Joye P, Cornelissen B, Lammens G, et al. Mass uniformity: influence of operational compression conditions on breakability of scored tablets as part of manufacturing robustness evaluation. J Food Drug Anal. 2005;13:22–9.
19.
go back to reference Van Vooren L, De Spiegeleer B, Thonissen T, Joye P, Van Durme J, Slegers G. Statistical analysis of tablet breakability methods. J Pharm Pharmaceut Sci. 2002;5:190–8. Van Vooren L, De Spiegeleer B, Thonissen T, Joye P, Van Durme J, Slegers G. Statistical analysis of tablet breakability methods. J Pharm Pharmaceut Sci. 2002;5:190–8.
20.
go back to reference Varaprasad A, Sriram N, Godwin Isaac Blessing A, Jawahar M, Thangamuthu S. Method development and validation of phenytoin sodium in bulk and its pharmaceutical dosage form by RP-HPLC method. Int J Biol Pharm Res. 2012;3:126–9. Varaprasad A, Sriram N, Godwin Isaac Blessing A, Jawahar M, Thangamuthu S. Method development and validation of phenytoin sodium in bulk and its pharmaceutical dosage form by RP-HPLC method. Int J Biol Pharm Res. 2012;3:126–9.
21.
go back to reference Kundu S, Gyadangi B. A simple, validated, single HPLC method for the determination of assay, dissolution, related substance of an antiepileptic drug in different pharmaceutical dosage form. Indo Am J Pharm Res. 2013;3:1722–32. Kundu S, Gyadangi B. A simple, validated, single HPLC method for the determination of assay, dissolution, related substance of an antiepileptic drug in different pharmaceutical dosage form. Indo Am J Pharm Res. 2013;3:1722–32.
23.
go back to reference Gupta RK, Singh UK, Kumar S, Moothan B. Estimation of sodium valproate in tablet dosage form by RP-HPLC without prior derivatization: application to dissolution studies. Int J Pharm Sci Drug Res. 2009;1:103–6. Gupta RK, Singh UK, Kumar S, Moothan B. Estimation of sodium valproate in tablet dosage form by RP-HPLC without prior derivatization: application to dissolution studies. Int J Pharm Sci Drug Res. 2009;1:103–6.
24.
go back to reference Karde M, Pawar H, Geevarghese R, Khatri J. Development and validation of RP-HPLC method for estimation of valproic acid in dissolution study of its formulation. Int J Pharmacy Pharm Sci. 2012;4(Suppl 5):201–6. Karde M, Pawar H, Geevarghese R, Khatri J. Development and validation of RP-HPLC method for estimation of valproic acid in dissolution study of its formulation. Int J Pharmacy Pharm Sci. 2012;4(Suppl 5):201–6.
25.
go back to reference Miller RB, Vranderick M. A validated HPLC method for the determination of carbamazepine and carbamazepine 10,11-epoxide in human plasma. J Liq Chromatogr Relat Technol. 1993;16:1249–61.CrossRef Miller RB, Vranderick M. A validated HPLC method for the determination of carbamazepine and carbamazepine 10,11-epoxide in human plasma. J Liq Chromatogr Relat Technol. 1993;16:1249–61.CrossRef
26.
go back to reference Dalmora SL, da Sangoi MS, Nogueira DR, D’Avila FB, Moreno RA, Sverdloff CE, et al. Determination of phenobarbital in human plasma by a specific liquid chromatography method: application to a bioequivalence study. Quím Nova. 2010;33:124–9. Dalmora SL, da Sangoi MS, Nogueira DR, D’Avila FB, Moreno RA, Sverdloff CE, et al. Determination of phenobarbital in human plasma by a specific liquid chromatography method: application to a bioequivalence study. Quím Nova. 2010;33:124–9.
27.
go back to reference Prasad CVN, Kumari CHS, Reddy BS, Sriramulu J. New RP-HPLC method for the determination of valproic acid in human plasma. J Pharm Sci Res. 2010;2:355–9. Prasad CVN, Kumari CHS, Reddy BS, Sriramulu J. New RP-HPLC method for the determination of valproic acid in human plasma. J Pharm Sci Res. 2010;2:355–9.
28.
go back to reference Szende V, Silvia I, Vari C, Titica DM, Daniela-Lucia M, Carmen C, et al. Determination of valproic acid in human plasma by high-performance liquid chromatography with mass spectrometry detection. Acta Medica Marisiensis. 2012;58:54–8. Szende V, Silvia I, Vari C, Titica DM, Daniela-Lucia M, Carmen C, et al. Determination of valproic acid in human plasma by high-performance liquid chromatography with mass spectrometry detection. Acta Medica Marisiensis. 2012;58:54–8.
29.
go back to reference Cochren BE. Splitting bupropion extended-release tablets. Am J Health Syst Pharm. 1999;56:575.PubMed Cochren BE. Splitting bupropion extended-release tablets. Am J Health Syst Pharm. 1999;56:575.PubMed
30.
go back to reference Zhao N, Zidan A, Tawakkul M, Sayeed VA, Khan M. Tablet splitting: product quality assessment of metoprolol succinate extended release tablets. Int J Pharm. 2010;401:25–31.CrossRefPubMed Zhao N, Zidan A, Tawakkul M, Sayeed VA, Khan M. Tablet splitting: product quality assessment of metoprolol succinate extended release tablets. Int J Pharm. 2010;401:25–31.CrossRefPubMed
31.
go back to reference Parra D, Beckey NP, Raval HS, Schnacky KR, Calabrese V, Coakley RW, et al. Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol. Am J Cardiol. 2005;95:1481–3.CrossRefPubMed Parra D, Beckey NP, Raval HS, Schnacky KR, Calabrese V, Coakley RW, et al. Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol. Am J Cardiol. 2005;95:1481–3.CrossRefPubMed
32.
go back to reference Gee M, Hasson NK, Hahn T, Ryono R. Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance. J Manag Care Pharm. 2002;8:453–8.PubMed Gee M, Hasson NK, Hahn T, Ryono R. Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance. J Manag Care Pharm. 2002;8:453–8.PubMed
33.
go back to reference Berg C, Ekedahl A. Dosages involving splitting tablets: common but unnecessary?: Dosages involving splitting tablets. J Pharm Health Serv Res. 2010;1:137–41.CrossRef Berg C, Ekedahl A. Dosages involving splitting tablets: common but unnecessary?: Dosages involving splitting tablets. J Pharm Health Serv Res. 2010;1:137–41.CrossRef
34.
go back to reference Chou CY, Hsu CC, Chiang SC, Ho CC, Chou CL, Wu MS, et al. Association between physician specialty and risk of prescribing inappropriate pill splitting. PLoS One. 2013;8:e70113.CrossRefPubMedPubMedCentral Chou CY, Hsu CC, Chiang SC, Ho CC, Chou CL, Wu MS, et al. Association between physician specialty and risk of prescribing inappropriate pill splitting. PLoS One. 2013;8:e70113.CrossRefPubMedPubMedCentral
35.
go back to reference Arnet I, von Moos M, Hersberger KE. Wrongly prescribed half tablets in a swiss university hospital. Int J Clin Med. 2012;3:637–43.CrossRef Arnet I, von Moos M, Hersberger KE. Wrongly prescribed half tablets in a swiss university hospital. Int J Clin Med. 2012;3:637–43.CrossRef
36.
go back to reference Rosenberg JM, Nathan JP, Plakogiannis F. Weight variability of pharmacist-dispensed split tablets. J Am Pharm Assoc (Wash). 2002;42:200–5.CrossRef Rosenberg JM, Nathan JP, Plakogiannis F. Weight variability of pharmacist-dispensed split tablets. J Am Pharm Assoc (Wash). 2002;42:200–5.CrossRef
37.
go back to reference Habib WA, Alanizi AS, Abdelhamid MM, Alanizi FK. Accuracy of tablet splitting: Comparison study between hand splitting and tablet cutter. Saudi Pharm J. 2014;22:454–9.CrossRefPubMed Habib WA, Alanizi AS, Abdelhamid MM, Alanizi FK. Accuracy of tablet splitting: Comparison study between hand splitting and tablet cutter. Saudi Pharm J. 2014;22:454–9.CrossRefPubMed
38.
go back to reference Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. Tablet-splitting: a common yet not so innocent practice: tablet-splitting. J Adv Nurs. 2011;67:26–32.CrossRefPubMed Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. Tablet-splitting: a common yet not so innocent practice: tablet-splitting. J Adv Nurs. 2011;67:26–32.CrossRefPubMed
39.
go back to reference Zaid AN, Ghosh AA. Compliance of scored tablet halves produced by Palestinian Pharmaceutical Companies with the new European Pharmacopoeia requirements. Arch Pharm Res. 2011;34:1183–9.CrossRefPubMed Zaid AN, Ghosh AA. Compliance of scored tablet halves produced by Palestinian Pharmaceutical Companies with the new European Pharmacopoeia requirements. Arch Pharm Res. 2011;34:1183–9.CrossRefPubMed
40.
go back to reference Stimpel M, Vetter H, Küffer B, Groth H, Greminger P, Vetter W. The scored tablet: a source of error in drug dosing? J Hypertens. 1985;3:S97–9.CrossRef Stimpel M, Vetter H, Küffer B, Groth H, Greminger P, Vetter W. The scored tablet: a source of error in drug dosing? J Hypertens. 1985;3:S97–9.CrossRef
41.
go back to reference Volpe DA, Gupta A, Ciavarella AB, Faustino PJ, Sayeed VA, Khan MA. Comparison of the stability of split and intact gabapentin tablets. Int J Pharm. 2008;350:65–9.CrossRefPubMed Volpe DA, Gupta A, Ciavarella AB, Faustino PJ, Sayeed VA, Khan MA. Comparison of the stability of split and intact gabapentin tablets. Int J Pharm. 2008;350:65–9.CrossRefPubMed
42.
go back to reference Pouplin T, Phuong PN, Toi PV, Nguyen Pouplin J, Farrar J. Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets. PLoS One. 2014;9:e102047. Pouplin T, Phuong PN, Toi PV, Nguyen Pouplin J, Farrar J. Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets. PLoS One. 2014;9:e102047.
43.
go back to reference Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash). 2002;42:195–9.CrossRef Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash). 2002;42:195–9.CrossRef
44.
go back to reference Hill S, Varker AS, Karlage K, Myrdal PB. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. J Manag Care Pharm. 2009;15:253–61.PubMed Hill S, Varker AS, Karlage K, Myrdal PB. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. J Manag Care Pharm. 2009;15:253–61.PubMed
Metadata
Title
Tablet Splitting of Antiepileptic Drugs in Pediatric Epilepsy: Potential Effect on Plasma Drug Concentrations
Authors
Ravi Prasad Nidanapu
Sundaram Rajan
Subramanian Mahadevan
Batmanabane Gitanjali
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2016
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-016-0193-1

Other articles of this Issue 6/2016

Pediatric Drugs 6/2016 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees